ALKS
Alkermes Plc
NASDAQ · Healthcare · Biotechnology · IE
$45.15
−1.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.5B | 1.6B | 1.7B | 1.1B |
| Cost of Revenue | 300.1M | 196.5M | 245.3M | 253.0M | 218.1M |
| Gross Profit | 1.5B | 1.3B | 1.3B | 1.4B | 893.7M |
| Operating Expenses | |||||
| R&D Expense | 430.4M | 324.0M | 245.3M | 270.8M | 272.7M |
| SG&A Expense | 881.2M | 714.5M | 645.2M | 689.8M | 590.8M |
| General & Admin Expense | 481.6M | 624.8M | 199.0M | 199.6M | 198.5M |
| Selling & Marketing Expense | 399.6M | 89.7M | 446.2M | 490.2M | 392.2M |
| Other Expenses | 77.6M | (13.0M) | 1.1M | 35.7M | 36.4M |
| Total Operating Expenses | 1.4B | 1.0B | 891.7M | 996.2M | 899.8M |
| Cost and Expenses | 1.7B | 1.2B | 1.1B | 1.2B | 1.1B |
| Operating Income (EBIT) | 64.2M | 254.0M | 420.6M | 414.1M | (6.1M) |
| Non-Operating | |||||
| Interest Income | 32.5M | 45.3M | 42.5M | 30.9M | 7.6M |
| Interest Expense | 86.6M | 12.3M | 22.6M | 23.0M | 13.0M |
| Net Interest Income | (54.1M) | 33.0M | 19.9M | 7.8M | (5.4M) |
| Other Non-Op Income/Expense | (52.9M) | 37.5M | 23.1M | 7.4M | (25.0M) |
| Non-Operating Income (excl Interest) | (33.7M) | (49.8M) | (45.7M) | (30.4M) | 12.0M |
| EBT (Pre-Tax Income) | 11.3M | 291.4M | 443.8M | 421.5M | (31.1M) |
| Income Tax Expense | 11.7M | 49.8M | 71.6M | (97.6M) | 2.0M |
| Bottom Line | |||||
| Net Income | (351.0K) | 241.7M | 367.1M | 355.8M | (158.3M) |
| Earnings from Cont. Ops | (351.0K) | 241.7M | 372.1M | 519.2M | (33.2M) |
| Earnings from Discont. Ops | — | — | (5.1M) | (163.4M) | (125.1M) |
| Bottom Line Net Income | (351.0K) | 241.7M | 367.1M | 355.8M | (158.3M) |
| Per Share | |||||
| Basic EPS | $0.00 | $1.47 | $2.22 | $2.14 | ($0.97) |
| Diluted EPS | ($0.02) | $1.43 | $2.17 | $2.10 | ($0.97) |
| Revenue Per Share | $10.45 | $8.96 | $9.42 | $10.01 | $6.79 |
| Shares | |||||
| Basic Shares Outstanding | 167.9M | 164.7M | 165.4M | 166.2M | 163.7M |
| Diluted Shares Outstanding | 176.4M | 168.7M | 169.2M | 169.7M | 163.7M |
| Profitability Metrics | |||||
| EBITDA | 178.7M | 330.9M | 494.9M | 519.5M | 59.8M |
| D&A | 80.7M | 27.2M | 28.5M | 74.9M | 77.9M |
| EBIT | 98.0M | 303.7M | 466.3M | 444.6M | (18.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026